Where to start: How to gain a foothold in the China biopharmaceutical market

May 9, 2017 Erin Righetti

The China pharmaceutical market has come of age. With record breaking investments in innovative companies, support from the CFDA, and new product approvals pending, China has entered a new age as a global competitor in new drug development and commercialization. China remains the second largest global economy, with USD 5.3 billion+ in VC investment in the life sciences sector in 2016. There are more market entry opportunities than ever before.

ChinaBio® Group, a leading consulting and advisory partner with significant experience in China’s life science industry, has put together an insider’s list of the Top 100* pharmaceutical companies in China to make it easier for life science BD teams to scout and pursue successful cross-partnerships with China-based companies.

Download the “Top 100 pharmaceutical companies in China” list now.

To meet and partner with over 900 global executives from pharma, biotech, finance and cross-border partners, register to attend ChinaBio® Partnering Forum taking place in Zhuhai, China, May 31–June 1, 2017.

*ranking based on revenue, recognition factor, partnering ability, and other criteria selected by ChinaBio® Group

 

 

About the Author

Erin Righetti

Editor-in-Chief, Insight

Follow on Twitter More Content by Erin Righetti
Previous Video
How can startup companies get noticed by potential investors and partners?
How can startup companies get noticed by potential investors and partners?

Access the industry's premier life science partnering event, BioPharm America™ in Boston September 26–27, 2...

Next Video
BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs
BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs

Dr. Kevin Cox, CEO of Imanova, the UK-based translational biomedical imaging company, explains to Scrip’s M...